Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-term Investments (2016 - 2025)

Zevra Therapeutics' Short-term Investments history spans 7 years, with the latest figure at $128.6 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 260.13% year-over-year to $128.6 million; the TTM value through Dec 2025 reached $128.6 million, up 260.13%, while the annual FY2025 figure was $128.6 million, 260.13% up from the prior year.
  • Short-term Investments reached $128.6 million in Q4 2025 per ZVRA's latest filing, down from $145.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $154.9 million in Q2 2025 to a low of $1.3 million in Q1 2022.
  • Average Short-term Investments over 4 years is $49.9 million, with a median of $25.3 million recorded in 2025.
  • Peak YoY movement for Short-term Investments: crashed 51.69% in 2024, then soared 1449.3% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $16.9 million in 2022, then skyrocketed by 46.08% to $24.7 million in 2023, then surged by 44.65% to $35.7 million in 2024, then skyrocketed by 260.13% to $128.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Short-term Investments are $128.6 million (Q4 2025), $145.1 million (Q3 2025), and $154.9 million (Q2 2025).